JP2016520599A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520599A5
JP2016520599A5 JP2016515625A JP2016515625A JP2016520599A5 JP 2016520599 A5 JP2016520599 A5 JP 2016520599A5 JP 2016515625 A JP2016515625 A JP 2016515625A JP 2016515625 A JP2016515625 A JP 2016515625A JP 2016520599 A5 JP2016520599 A5 JP 2016520599A5
Authority
JP
Japan
Prior art keywords
seq
use according
protein
human origin
egf domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016515625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520599A (ja
JP6503342B2 (ja
Filing date
Publication date
Priority claimed from CN201410182727.6A external-priority patent/CN104211799B/zh
Application filed filed Critical
Publication of JP2016520599A publication Critical patent/JP2016520599A/ja
Publication of JP2016520599A5 publication Critical patent/JP2016520599A5/ja
Application granted granted Critical
Publication of JP6503342B2 publication Critical patent/JP6503342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016515625A 2013-05-29 2014-05-19 ヒト起源egfドメインタンパク質及びその使用 Active JP6503342B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201310206726 2013-05-29
CN201310206726.6 2013-05-29
CN201410182727.6 2014-04-30
CN201410182727.6A CN104211799B (zh) 2013-05-29 2014-04-30 人源egf结构域蛋白及其应用
PCT/CN2014/077789 WO2014190860A1 (zh) 2013-05-29 2014-05-19 人源egf结构域蛋白及其应用

Publications (3)

Publication Number Publication Date
JP2016520599A JP2016520599A (ja) 2016-07-14
JP2016520599A5 true JP2016520599A5 (https=) 2017-06-29
JP6503342B2 JP6503342B2 (ja) 2019-04-17

Family

ID=51987987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515625A Active JP6503342B2 (ja) 2013-05-29 2014-05-19 ヒト起源egfドメインタンパク質及びその使用

Country Status (5)

Country Link
US (1) US9833497B2 (https=)
EP (1) EP3006460B1 (https=)
JP (1) JP6503342B2 (https=)
CN (2) CN104211799B (https=)
WO (1) WO2014190860A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016019484A2 (pt) * 2014-02-28 2017-10-24 3B Pharmaceuticals Gmbh peptídeos e métodos de uso
US10550163B2 (en) 2014-04-03 2020-02-04 The Regents Of The University Of California Peptide fragments of netrin-1 and compositions and methods thereof
US11319343B2 (en) * 2017-06-30 2022-05-03 Royal Melbourne Institute Of Technology Method of treatment
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2022217037A1 (en) * 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Compositions and methods for treatment of chronic lung diseases
EP4198045A1 (en) * 2021-12-16 2023-06-21 Université de Lille Antimicrobial peptides, variants and chemical analogues thereof and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322264A1 (en) * 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue
EP1636358A2 (en) * 2003-06-05 2006-03-22 Canadian Blood Services Mutants of the factor vii epidermal growth factor domain
US20090131310A1 (en) * 2004-05-13 2009-05-21 Ho Samuel B Mucin3 egf-like domains
US20110212108A1 (en) * 2008-05-09 2011-09-01 The Regents Of The University Of California Neuregulin/erbb signaling and integrin
WO2010006136A2 (en) * 2008-07-09 2010-01-14 Mayo Foundation For Medical Education And Research Adenovirus targeting
CN102596231B (zh) * 2009-06-25 2016-01-20 北卡罗来纳-查佩尔山大学 嵌合因子ⅶ分子
SG10201505217WA (en) * 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors

Similar Documents

Publication Publication Date Title
JP2016520599A5 (https=)
Lopes et al. The role of antimicrobial peptides as antimicrobial and antibiofilm agents in tackling the silent pandemic of antimicrobial resistance
Masso-Silva et al. Antimicrobial peptides from fish
JP2012530509A5 (https=)
CY1123138T1 (el) Κυτταροτοξικες πρωτεϊνες που περιλαμβανουν περιοχες δεσμευσης στοχευσης-κυtταρων και περιοχες α υπομοναδας τοξινης shiga για επιλεκτικη θανατωση συγκεκριμενων κυτταρικων τυπων
MX2020006098A (es) Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
BR112019011660A2 (pt) composições de bacteriófagos que compreendem fagos antibacterianos respiratórios e métodos de uso das mesmas
EA201270774A1 (ru) Способ уменьшения биопленок
EA201990551A1 (ru) Антибиотические соединения
GB201018518D0 (en) Novel endolysin
AU2011206532A8 (en) Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
JP2014500714A5 (https=)
EA201990091A1 (ru) Способ получения и очистки натриевой соли гиалуроновой кислоты
EP4606375A3 (en) Antibacterial compounds
EP4477272A3 (en) Polymyxin derivatives as antimicrobial compounds
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
JP2016505007A5 (https=)
HRP20241279T1 (hr) Pripravak koji sadrži probiotike koji prekomjerno eksprimiraju protein clpb za uporabu u liječenju pretilosti
MX2019014935A (es) Antagonistas muscarinicos y sus combinaciones para el tratamiento de enfermedades de las vias respiratorias en caballos.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
EA201991233A1 (ru) Новый эндолизин
CL2017002668A1 (es) Tratamiento de infecciones bacterianas en la acuicultura
MX2019007902A (es) Composiciones para el tratamiento de seres humanos.
JP2016521685A5 (https=)
WO2010125196A3 (en) Bacteriophages specific to pak and cha strains of pseudomonas aeruginosa and their applications